【编号】:PR0791
【产品名称】:7,2′-二羟基-3′,4′-二甲氧基异黄烷对照品
【规格】:10mg
【用途】:
【编号】:PR0791
【产品名称】:7,2′-二羟基-3′,4′-二甲氧基异黄烷对照品
【规格】:10mg
【用途】:
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Dolasetron Mesylate (Synonyms: MDL-73147EF)
Dolasetron Mesylate (MDL-73147EF) 是 5-HT3 受体拮抗剂,有潜力用于化疗引起的恶心和呕吐。
Dolasetron Mesylate Chemical Structure
CAS No. : 115956-13-3
规格 | 是否有货 | ||
---|---|---|---|
100 mg | 询价 | ||
250 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Dolasetron Mesylate 的其他形式现货产品:
生物活性 |
Dolasetron Mesylate (MDL-73147EF) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy. |
|
---|---|---|
IC50 & Target |
|
|
Clinical Trial |
|
|
分子量 |
420.48 |
|
Formula |
C20H24N2O6S |
|
CAS 号 |
115956-13-3 |
|
中文名称 |
多拉司琼甲磺酸盐 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
|
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Sodium stibogluconate (Synonyms: Stibogluconate trisodium nonahydrate) 纯度: ≥98.0%
Sodium stibogluconate (Stibogluconate trisodium nonahydrate) 是蛋白酪氨酸磷酸酶 (phosphatase) 的有效抑制剂。 Sodium stibogluconate 在10,100 和 100 μg/mL 时分别抑制 99% 的 SHP-1,SHP-2 和 PTP1B 活性。
Sodium stibogluconate Chemical Structure
CAS No. : 16037-91-5
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
500 mg | ¥550 | In-stock | |
1 g | ¥800 | In-stock | |
5 g | 询价 | ||
10 g | 询价 |
* Please select Quantity before adding items.
生物活性 |
Sodium stibogluconate (Stibogluconate trisodium nonahydrate) is a potent inhibitor of protein tyrosine phosphatase. Sodium stibogluconate inhibits 99% of SHP-1, SHP-2 and PTP1B activity at 10, 100, 100 μg/mL, respectively. |
IC50 & Target |
Phosphatase[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Sodium stibogluconate (Stibogluconate trisodium nonahydrate) inhibits 99% of SHP-1 activity at 10 μg/mL, a therapeutic concentration of the drug for leishmaniasis. Similar degrees of inhibition of SHP-2 and PTP1B required 100 μg/mL Sodium stibogluconate. The inhibition of cellular PTPases by the Sodium stibogluconate is suggested by its rapid induction of tyrosine phosphorylation of cellular proteins in Baf3 cells and its augmentation of IL-3-induced Janus family kinase 2/Stat5 tyrosine phosphorylation and proliferation of Baf3 cells. The augmentation of the opposite effects of GM-CSF and IFN-α on TF-1 cell growth by Sodium stibogluconate indicate its broad activities in the signaling of various cytokines[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
Sodium stibogluconate (Stibogluconate trisodium nonahydrate) induces 61% growth inhibition of Renca tumors in BALB/c mice coincident with an increase (2-fold) in tumor-infiltrating macrophages. A combination of Sodium stibogluconate and IL-2 is more effective in inhibiting tumor growth (91%) and inducing tumor-infiltrating (4-fold), whereas IL-2 alone has little effect[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
910.90 |
||||||||||||||||
Formula |
C12H38Na3O26Sb2 |
||||||||||||||||
CAS 号 |
16037-91-5 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
溶解性数据 |
In Vitro:
H2O : 3 mg/mL (3.29 mM; ultrasonic and warming and heat to 60°C) DMSO : 1 mg/mL (1.10 mM; Need ultrasonic and warming) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
Human myeloid cell line TF-1 is maintained in RPMI 1640 supplemented with 10% FCS and 40 ng/mL recombinant human GM-CSF. For cell proliferation assays, cells are washed in 10% FCS medium twice, resuspended in 10% FCS medium, incubated at 37°C for 16 h, and then cultured at 37°C in 10% FCS medium containing various amounts of cytokines, sodium stibogluconate, or potassium antimonyl tartrate for 3-6 days. The cell numbers in proliferation assays are determined by an MTT assay or by microscopic cell counting[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [2] |
BALB/c and athymic nude BALB/c mice are inoculated (s.c.) at the flanks with Renca cells (106 cells/site). Four days after inoculation, the mice are subjected to no treatment (control) or treatment with IL-2 (105 IU/day for 5 days i.p.), Stibogluconate sodium (12 mg/day i.m. at hip regions), or the combination of the two agents for 2 wk. Tumor volume is measured during the study period and calculated using the formula for a prolate spheroid[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
AT13148 纯度: 99.42%
AT13148 是一种可口服的,ATP 竞争性的 AGC kinase 的抑制剂,能够抑制 Akt1/Akt2/Akt3,p70S6K,PKA 和 ROCKI/ROCKII 的活性,IC50 值分别为 38 nM/402 nM/50 nM,8 nM,3 nM 和 6 nM/4 nM。
AT13148 Chemical Structure
CAS No. : 1056901-62-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1483 | In-stock | |
5 mg | ¥1348 | In-stock | |
10 mg | ¥2278 | In-stock | |
50 mg | ¥5998 | In-stock | |
100 mg | ¥8788 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
AT13148 inhibits a panel of kinases at 10 μM, and the IC50 values for p70S6K, PKA, ROCKI, and ROCKII are all less than 10 nM and those for AKT1, 2, and 3 are 38, 402, and 50 nM, respectively. For the related AGC kinases RSK1 and SGK3, the IC50 values are 85 and 63 nM, respectively. In contrast, IC50 values for the non-AGC kinases CHK2 and Aurora B are both greater than 800 nM. AT13148 potently inhibits proliferation with GI50 values of 1.5 to 3.8 μM across a selected panel of cancer cell lines[1]. AT13148 treatment in gastric cancer cells dramatically suppresses activation of multiple AGC kinases, including Akt (at p-Thr-308), p70S6 kinase (p70S6K), glycogen synthase kinase 3β (GSK-3β) and p90 ribosomal S6 kinase (RSK)[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
Oral drug administration of 5 mg/kg of AT13148 results in complete bioavailability. Clear inhibition of phosphorylation of the AKT substrates GSK3β, tuberin, and the p70S6K target S6RP are also observed in PTEN-deficient MES-SA human uterine tumor xenografts after treatment with 40 and 50 mg/kg p.o. of AT13148[1]. Oral gavage of AT13148 at well-tolerated doses significantly inhibits HGC27 xenograft tumor growth in nude mice. AGC activity is also dramatically decreased in AT13148-administrated HGC27 tumors[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
313.78 |
||||||||||||||||
Formula |
C17H16ClN3O |
||||||||||||||||
CAS 号 |
1056901-62-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (159.35 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Kinase Assay [1] |
AT13148 is assayed against 40 kinases and the percentage inhibition at 10 μM of AT13148 is determined. Individual IC50 values are measured for selected kinases using ATP concentrations equivalent to the Km for each enzyme. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Cell Assay [2] |
Cells are seeded onto 96-well micro-plates at a density of 1×104 cells per well. After treatment, MTT solution (0.5 mg/mL) is added for 2-3 h. The MTT-purple formazan productions are dissolved in 0.1 N hydrochloric acid, and optical density (OD) is obtained through the micro-plate reader at 570 nm wavelength. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
Animal Administration [1] |
For pharmacokinetic analysis, male athymic BALB/c mice are obtained from Harlan. AT13148 is formulated in 10% DMSO, 1% Tween-20, and 89% saline and administered at 5 mg/kg i.v. or p.o. Duplicate samples of heparinized whole blood are collected by cardiac puncture at 1, 2, 4, 6, 8, 16, 24, and 72 hours after dosing. Plasma and tissues (liver, kidney, spleen, and muscle are also taken) are prepared and frozen at −20°C until analysis. AT13148 is extracted from plasma and tissues using acetonitrile containing an internal standard and quantified using a liquid chromatography tandem mass spectrometry (LC-MS/MS) method and appropriate standard curves. Pharmacokinetic parameters are determined using WinNonLin software version 5.2. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
AT7519 TFA (Synonyms: AT7519M TFA) 纯度: 98.53%
AT7519 (AT7519M) TFA 是一种有效的 CDK 抑制剂,对 CDK1,CDK2,CDK4-CDK6 以及 CDK9 的 IC50 值分别为 210,47,100,13,170 和 <10 nM。
AT7519 TFA Chemical Structure
CAS No. : 1431697-85-6
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥810 | In-stock | |
10 mg | ¥1350 | In-stock | |
50 mg | ¥4450 | In-stock | |
100 mg | ¥6900 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively. |
||||||||
---|---|---|---|---|---|---|---|---|---|
IC50 & Target[2] |
|
||||||||
体外研究 (In Vitro) |
AT7519 (0-4 μM) TFA results in dose-dependent cytotoxicity with IC50s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 TFA overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) TFA induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) TFA inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells[1]. AT7519 (250 nM) TFA inhibits cell cycle progression in human tumor cell lines. AT7519 TFA also induces apoptosis of human tumor cell lines[2]. AT7519 (100-700 nM) TFA induces apoptosis in leukemia cell lines. AT7519TFA also inhibits transcription in human tumor cell lines. Furthermore, AT7519 TFA inhibits RNA polymerase II and reduces antiapoptotic protein levels[3]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||
体内研究 (In Vivo) |
AT7519 TFA inhibits tumor growth in a human MM xenograft mouse model[1]. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) TFA also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice[2]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||
Clinical Trial |
|
||||||||
分子量 |
496.27 |
||||||||
Formula |
C18H18Cl2F3N5O4 |
||||||||
CAS 号 |
1431697-85-6 |
||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||
参考文献 |
|
Cell Assay [1] |
AT7519’s effects on viability of MM cell lines, primary MM cells, and PBMNCs is assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrasodium bromide (MTT) dye absorbance. DNA synthesis is measured by tritiated thymidine uptake (3H-TdR). MM cells (2-3 × 104 cells/well) are incubated in 96-well culture plates with media and different concentrations of AT7519 and/or recombinant IL-6 (10 ng/mL) or IGF-1 (50 ng/mL) for 24 or 48 h at 37°C and 3H-TdR incorporation is measured. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [1] |
To evaluate the in vivo anti-MM activity of AT7519, male SCID mice are inoculated subcutaneously with 5×106 MM.1S cells in 100 μL serum-free RPMI 1640 medium. When tumors are measurable, mice are treated intraperitoneally (IP) with vehicle or AT7519 dissolved in saline 0.9%. The first group of 10 mice is treated with 15 mg/kg once a day for five days for 2 weeks, and the second group is treated with 15 mg/kg once a day three times a week for four consecutive weeks. The control group receives the carrier alone at the same schedule. Tumor size is measured every alternate day in 2 dimensions using calipers, and tumor volume is calculated with the formula: V= 0.5 a × b2 (a= long diameter of the tumor, b= short diameter of the tumor). Animals are sacrificed when the tumor reaches 2 cm3 or when the tumor is ulcerated. Survival and tumor growth are evaluated from the first day of treatment until death. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
AT7519 (Synonyms: AT7519M) 纯度: 99.76%
AT7519 (AT7519M) 是一种有效的 CDK 抑制剂,对 CDK1,CDK2,CDK4-CDK6 以及 CDK9 的 IC50 值分别为 210,47,100,13,170 和 <10 nM。
AT7519 Chemical Structure
CAS No. : 844442-38-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥891 | In-stock | |
5 mg | ¥810 | In-stock | |
10 mg | ¥1350 | In-stock | |
50 mg | ¥4450 | In-stock | |
100 mg | ¥6900 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[2] |
|
||||||||||||||||
体外研究 (In Vitro) |
AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC50s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells[1]. AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines[2]. AT7519 (100-700 nM) induces apoptosis in leukemia cell lines. AT7519 also inhibits transcription in human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
AT7519 inhibits tumor growth in a human MM xenograft mouse model[1]. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
382.24 |
||||||||||||||||
Formula |
C16H17Cl2N5O2 |
||||||||||||||||
CAS 号 |
844442-38-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (130.81 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
AT7519’s effects on viability of MM cell lines, primary MM cells, and PBMNCs is assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrasodium bromide (MTT) dye absorbance. DNA synthesis is measured by tritiated thymidine uptake (3H-TdR). MM cells (2-3 × 104 cells/well) are incubated in 96-well culture plates with media and different concentrations of AT7519 and/or recombinant IL-6 (10 ng/mL) or IGF-1 (50 ng/mL) for 24 or 48 h at 37°C and 3H-TdR incorporation is measured. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [1] |
To evaluate the in vivo anti-MM activity of AT7519, male SCID mice are inoculated subcutaneously with 5×106 MM.1S cells in 100 μL serum-free RPMI 1640 medium. When tumors are measurable, mice are treated intraperitoneally (IP) with vehicle or AT7519 dissolved in saline 0.9%. The first group of 10 mice is treated with 15 mg/kg once a day for five days for 2 weeks, and the second group is treated with 15 mg/kg once a day three times a week for four consecutive weeks. The control group receives the carrier alone at the same schedule. Tumor size is measured every alternate day in 2 dimensions using calipers, and tumor volume is calculated with the formula: V= 0.5 a × b2 (a= long diameter of the tumor, b= short diameter of the tumor). Animals are sacrificed when the tumor reaches 2 cm3 or when the tumor is ulcerated. Survival and tumor growth are evaluated from the first day of treatment until death. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
【编号】:VIP(XL)80352
【产品名称】:雷尼酸锶对照品
【规格】:5mg;98%
【用途】:
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
AT7867 纯度: 99.83%
AT7867 是一种 ATP 竞争性的 Akt1/Akt2/Akt3 和 p70S6K/PKA 抑制剂,IC50 分别为 32 nM/17 nM/47 nM 和 85 nM/20 nM。
AT7867 Chemical Structure
CAS No. : 857531-00-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1320 | In-stock | |
5 mg | ¥1200 | In-stock | |
10 mg | ¥1600 | In-stock | |
50 mg | ¥6000 | In-stock | |
100 mg | ¥9500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
The inhibition of AKT2 by AT7867 is shown to be ATP-competitive with a Ki of 18nM. AT7867 also displays potent activity against the structurally related AGC kinases p70S6K and PKA, but shows a clear window of selectivity against kinases from other kinase sub-families. In vitro growth inhibition studies show that AT7867 blocks proliferation in a number of human cancer cell lines. AT7867 appears to be most potent at inhibiting proliferation in MES-SA uterine, MDA-MB-468 and MCF-7 breast, and HCT116 and HT29 colon lines (IC50 values range from 0.9-3 μM), and least effective in the two prostate lines tested (IC50 values range from 10-12 μM) [1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
In vivo: Following oral administration at 20 mg/kg, the elimination of AT7867 from plasma appears to be similar to that observed after i.v. administration. Plasma levels of AT7867 remain above 0.5 μM for at least 6 hours following an oral dose of 20 mg/kg. Assuming linear pharmacokinetics following i.v. administration, the bioavailability by the oral route is calculated to be 44%. In vivo pharmacodynamic (PD) biomarker studies are therefore performed with this model. Following pharmacokinetic and tolerability studies, doses of AT7867 (90 mg/kg p.o. or 20 mg/kg i.p.) are administered to athymic mice bearing MES-SA tumors and the phosphorylation status of GSK3β and S6RP in tumors is monitored over time. Clear inhibition of phosphorylation of the two markers of pathway activity is seen at 2 and 6 hours following treatment with AT7867. By 24 hours, total levels of both GSK3β and S6RP are greatly reduced[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
337.85 |
||||||||||||||||
Formula |
C20H20ClN3 |
||||||||||||||||
CAS 号 |
857531-00-1 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 10 mg/mL (29.60 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Kinase Assay [1] |
Kinase assays for AKT2, PKA, p70S6K and CDK2/cyclinA are all carried out in a radiometric filter binding format. Assay reactions are set up in the presence of compound. For AKT2, the AKT2 enzyme and 25 μM AKTide-2T peptide (HARKRERTYSFGHHA) are incubated in 20 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 10 μg/mL BSA and 30 μM ATP (1.16 Ci/mmol) for 4 hours. For PKA, the PKA enzyme and 50 μM peptide (GRTGRRNSI) are incubated in 2 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM orthovanadate, 1 mM DTT and 40 μM ATP (0.88 Ci/mmol) for 20 minutes. For p70S6K, the p70S6K enzyme and 25 μM peptide substrate (AKRRRLSSLRA) are incubated in 10 mM MOPS, pH 7, 0.2 mM EDTA, 1 mM MgCl2, 0.01% β-mercaptoethanol, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% glycerol and 15μM ATP (2.3 Ci/mmol) for 60 minutes. For CDK2, the CDK2/cyclinA enzyme and 0.12 μg/ml Histone H1 are incubated in 20 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 0.1 mg/ml BSA and 45 μM ATP (0.78 Ci/mmol) for 4 hours. Assay reactions are stopped by adding an excess of orthophosphoric acid and the stopped reaction mixture is then transferred to Millipore MAPH filter plates and filtered. The plates are then washed, scintillant added and radioactivity measured by scintillation counting on a Packard TopCount. IC50 values are calculated from replicate curves using GraphPad Prism software. AKT1 and 3 enzyme assays are carried out, while all other enzyme assays are performed[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Cell Assay [1] |
Cells are plated in 96-well microplates at 16,000 cells per well in medium supplemented with 10% FBS, and grown for 24 hours before treatment with AT7867. AT7867 or vehicle control are added to the cells for 1 hour. Following this, cells are fixed with 3% paraformaldehyde, 0.25% glutaraldehyde, 0.25% Triton-X100, washed and blocked with 5% milk in tris-buffered saline with 0.1% Tween-20 (TBST) prior to overnight incubation with a phospho-GSK3β (serine 9) antibody. The plates are then washed, secondary antibody added, and enhancement of the signal performed using DELFIA reagents. Europium counts are normalized to the protein concentration, and the IC50 value for each inhibitor is calculated in GraphPad Prism using non-linear regression analysis and a sigmoidal dose-response (variable slope) equation[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
Animal Administration [1] |
Mice[1] 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
【编号】:VIP(XL)80419
【产品名称】:硝酸芬替康唑对照品
【规格】:5mg;98%
【用途】:
贝兰伯Bioland叠装吸头-滤芯低吸附移液吸头 金畔生物主营:移液器吸头,荧光定量PCR耗材,PCR八联管,PCR孔板,光学平盖等等。
叠装吸头
Bioland 除了袋装与盒装包装规格,同时给大家带来了预装版叠装包装规格。预装版叠装包装比盒装更加经济。比袋装使用更加方便,无需在实验室无聊的插装吸头。
|
贝兰伯Bioland叠装吸头-滤芯低吸附移液吸头适应客户:医院检验科PCR实验室,中心实验室;第三方检测机构,科研院所,大专院校,制药厂,试剂生产厂家,疾控中心,检验检疫。
温馨提示:不可用于临床治疗。
1、针对IgG固定优化,对同时含有亲水性和疏水性区域的分子提供最佳的结合力。
2、标准ELISA检测的表面处理选择。
3、适用于固相免疫检测。
4、相当于其他制造商提供的“高结合力”板。
5、通过颜色标识可轻易识别:96孔标准板为蓝色浮凸式字母数字顺序标识。
6、不含内毒素、无DNase、DNA、RNase、无细胞毒性。
包装
包装规格 = 100个(独立包装)
BRANDplates® 微孔板
The new generation of microplates from BRAND!
现代研究技术要求高品质的耗材。BRANDplates ®,BRAND新一代的微孔板,
能应用于生命科学所有重要领域。在这个综合的产品线中,我们应用最新的技
术开发了三种全新的免疫分析表面与四种全新的细胞培养表面。最新的产品线
能够覆盖多数标准应用(如均相检测,筛选)与免疫和细胞培养领域的应用。
-未处理表面
pureGrade™
pureGrade™ S
-免疫检测表面
immunoGrade™
hydroGrade™
lipoGrade™
-细胞培养表面
cellGrade™
cellGrade™ plus
cellGrade™ premium
inertGrade™
BRANDplates® 现在已有超过130款不同的微孔板。
商品属性 | |
---|---|
商品名称 | Brand/普兰德 immunoGrade™ 免疫板 微孔板96孔 350ul (781729)-781729-Brand普兰德 |
型号 | 781729 |
类别 | 实验室耗材|||分子生物|||微孔板|||Brand/普兰德immunoGrade™免疫板微孔板96孔350ul(781729) |
品牌 | Brand普兰德 |
品牌简介 | Brand普兰德 |
关键字 | 微孔板 免疫板,微孔,免疫,普兰,表面,疏水,标准 |
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
AT9283 纯度: 99.70%
AT9283 是一种多靶点激酶抑制剂,有效抑制 Aurora A/B,JAK2/3,Abl (T315I),和 Flt3 (IC50 值范围为 1-30 nM)。AT9283 抑制多种实体瘤在体内外的生长和存活。
AT9283 Chemical Structure
CAS No. : 896466-04-9
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥923 | In-stock | |
2 mg | ¥770 | In-stock | |
5 mg | ¥1100 | In-stock | |
10 mg | ¥1750 | In-stock | |
50 mg | ¥5675 | In-stock | |
100 mg | ¥9360 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo[1][2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
AT9283 leads to a clear polyploid phenotype by inhibiting the activity of Aurora B kinase in HCT116 cells with IC50 of 30 nM. Furthermore, AT9283 also produces the potent inhibition on HCT116 colony formation[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
In HCT116 human colon carcinoma xenograft bearing mice, AT9283 treatment (15 mg/kg and 20 mg/kg) for 16 days results in a significant tumor growth inhibition of 67% and 76%, respectively. In addition, AT9283 also exhibits a significantly longer half-life in tumors (2.5 hours) compared with plasma (0.5 hour) and modest oral bioavailability in mice[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
381.43 |
||||||||||||||||
Formula |
C19H23N7O2 |
||||||||||||||||
CAS 号 |
896466-04-9 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 100 mg/mL (262.17 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Cell Assay [2] |
Lymphoma cells are seeded at 8,000 per well in 96-well culture plates and allowed to grow for 24 hr followed by the desired treatment with increasing concentrations of the indicated agents for 4 days. Viable cell densities are determined using a CellTiter 96 Cell Proliferation Assay. The IC50 values are estimated by Calcusyn software. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [2] |
SCID mice are injected with 1×107 Granta-519 MCL cells subcutaneously into the right hind flank. When tumors reached a volume of appr 60-100 mm3, mice are divided randomly (pair-matched) into six test groups with 12 mice per cohort: control group (saline), AT9283 (15 mg/kg IP Q1D, 5 days a week × 3 weeks) group, AT9283 (20 mg/kg IP Q1D, 5 days a week × 3 weeks) group, docetaxel (10 mg/kg IV Q1W × 3 weeks) group, AT9283 (15 mg/kg IP Q1D, 5 days a week × 3 weeks) + docetaxel (10 mg/kg IV Q1W × 3 weeks) group and AT9283 (20 mg/kg IP Q1D, 5 days a week × 3 weeks) + docetaxel (10 mg/kg IV Q1W × 3 weeks) group. The length (L) and width (W) of the subcutaneous tumors are measured by calipers and the tumor volume (TV) is calculated as: TV=(L × W2)/2. Mice are sacrificed at the end of study and overall survival for each cohort is analyzed by Kaplan–Meier method. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
产品名称 | 红霉素A二水合物 |
---|---|
英文名称 | Erythromycin A dihydrate |
运输条件 | 常规运输 |
CAS编号 | 59319-72-1 |
---|---|
储存温度 | 室温 |
RTECS | KF4375000 |
分子量 | 769.96 |
分子式 | C₃₇H₆₇NO₁₃・2H₂O |
EC号 | 204-040-1 |
品牌 | Jinpan |
Smiles | CCC1[C@H]([C@@H](C(C(=O)[C@H](C[C@H]([C@H](C([C@H]([C@@H](C(=O)O1)C)O[C@H]2C[C@@]([C@ |
PubChem CID | 83991 |
【编号】:YJ420011
【产品名称】:*▲间苯三酚对照品
【规格】:100 mg/支
【用途】:供含量测定用
推荐阅读:购买此类毒性对照品标准品需要提供的资料
大鼠血管紧张素1型受体(AT1)ELISA试剂盒金畔生物公司供应:ELISA试剂盒,血清,荧光定量PCR耗材,移液器吸嘴,微量离心管,进口冻存管,细胞培养皿,培养板,培养瓶,吸头,仪器及手套,色谱耗材,针头过滤器。
货号:BS-3525
规格:96T/48T
产品名:大鼠血管紧张素1型受体(AT1)ELISA检测试剂盒
检测种属:人、大小鼠、豚鼠、兔子、猪、犬、牛羊、鸡鸭、猴ELISA试剂盒等种属。
保存条件及有效期:
1、试剂盒保存:2-8℃。
2、有效期:6个月
标记物:血清、血浆、组织匀浆等
【测试种属】犬、大小鼠、人、豚鼠、兔子、牛羊、猪、鸡鸭elisa试剂盒等种属
【储存方式】:2-8℃
【检测目的】用于测定血清,血浆及相关液体等样本。例如适合检测包括血清、血浆、尿液、胸腹水、灌洗液、脑脊液、细胞培养上清、组织匀浆等标本。
【用途】科研实验,不用于临床诊断。
大鼠血管紧张素1型受体(AT1)ELISA试剂盒
样本处理及要求:
1. 血清:室温血液自然凝固10-20分钟,离心20分钟左右(2000-3000转/分)。仔细收集上清,保存过程中如出现沉淀,应再次离心。
2. 血浆:应根据标本的要求选择EDTA或柠檬酸钠作为抗凝剂,混合10-20分钟后,离心20分钟左右(2000-3000转/分)。仔细收集上清,保存过程中如有沉淀形成,应该再次离心。
3. 尿液:用无菌管收集,离心20分钟左右(2000-3000转/分)。仔细收集上清,保存过程中如有沉淀形成,应再次离心。胸腹水、脑脊液参照实行。
4. 细胞培养上清:检测分泌性的成份时,用无菌管收集。离心20分钟左右(2000-3000转/分)。仔细收集上清。检测细胞内的成份时,用PBS(PH7.2-7.4)稀释细胞悬液,细胞浓度达到100万/ml左右。通过反复冻融,以使细胞破坏并放出细胞内成份。离心20分钟左右(2000-3000转/分)。仔细收集上清。保存过程中如有沉淀形成,应再次离心。
5. 组织标本:切割标本后,称取重量。加入一定量的PBS,PH7.4。用液氮迅速冷冻保存备用。标本融化后仍然保持2-8℃的温度。加入一定量的PBS(PH7.4),用手工或匀浆器将标本匀浆充分。离心20分钟左右(2000-3000转/分)。仔细收集上清。分装后一份待检测,其余冷冻备用。
6. 标本采集后尽早进行提取,提取按相关文献进行,提取后应尽快进行实验。若不能马上进行试验,可将标本放于-20℃保存,但应避免反复冻融.
7. 不能检测含NaN3的样品,因NaN3抑制辣根过氧化物酶的(HRP)活性。
大鼠血管紧张素1型受体(AT1)ELISA检测试剂盒注意事项:
1.试剂盒从冷藏环境中取出应在室温平衡15-30分钟后方可使用,酶标包被板开封后如未用完,板条应装入密封袋中保存。
2.浓洗涤液可能会有结晶析出,稀释时可在水浴中加温助溶,洗涤时不影响结果。
3.各步加样均应使用加样器,并经常校对其准确性,以避免试验误差。一次加样时间最好控制在5分钟内,如标本数量多,推荐使用排枪加样。
4.请每次测定的同时做标准曲线,最好做复孔。如标本中待测物质含量过高(样本OD值大于标准品孔第一孔的OD值),请先用样品稀释液稀释一定倍数(n倍)后再测定,计算时请最后乘以总稀释倍数(×n×5)。
5.封板膜只限一次性使用,以避免交叉污染。
6.底物请避光保存。
7.严格按照说明书的操作进行,试验结果判定必须以酶标仪读数为准.
8.所有样品,洗涤液和各种废弃物都应按传染物处理。
9.本试剂不同批号组分不得混用。
10.如与英文说明书有异,以英文说明书为准。
大鼠血管紧张素1型受体(AT1)ELISA检测试剂盒操作步骤:
检测试剂盒组成:
试剂盒组成48 孔配置96 孔配置保存
说明书1 份1 份
封板膜2 片(48)2 片(96)
密封袋1 个1 个
酶标包被板1×481×962-8℃保存
标准品:540μg/L0.5ml×1 瓶0.5ml×1 瓶2-8℃保存
标准品稀释液1.5ml×1 瓶1.5ml×1 瓶2-8℃保存
酶标试剂3 ml×1 瓶6 ml×1 瓶2-8℃保存
样品稀释液3 ml×1 瓶6 ml×1 瓶2-8℃保存
显色剂 A 液3 ml×1 瓶6 ml×1 瓶2-8℃保存
显色剂 B 液3 ml×1 瓶6 ml×1 瓶2-8℃保存
终止液3 ml×1 瓶6 ml×1 瓶2-8℃保存
浓缩洗涤液(20ml×20 倍)×1 瓶(20ml×30 倍)×1 瓶2-8℃保存
2.0ml;可立;带不透明螺旋系盖琥珀色样品管;蓝色盖
1.5ml;不可立;带不透明螺旋系盖琥珀色样品管;琥珀色盖;无菌
Multi-use Rack,PP,21wells
Multi-use Rack,PP,90wells
Western 孵育盒 6分格, 黑色,硅化处理(低吸附抗体),103 x 76 x 33mm
离心机
人胰岛素自身抗体试剂盒(IAA)ELISA检测试剂盒
人胰多肽试剂盒(PP)ELISA检测试剂盒
人胰高血糖素试剂盒(GC)ELISA检测试剂盒
人胰激肽原酶试剂盒(PK)ELISA检测试剂盒
人胰抑制素试剂盒(Pancreastatin)ELISA检测试剂盒
人分泌型免疫球蛋白A试剂盒(SIgA)ELISA检测试剂盒
人晚期糖基化终末产物试剂盒(AGEs)ELISA检测试剂盒
人网膜素试剂盒(omentin)ELISA检测试剂盒
人Toll样受体9试剂盒(TLR-9/CD289)ELISA检测试剂盒
产品用途:可用于科研实验,不用于临床治疗!
产品名称 | 二甲胺四环素盐酸盐 |
---|---|
英文名称 | Minocycline hydrochloride |
别名 | 盐酸米诺环素,盐酸二甲胺四环素 |
英文别名 | [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide |
规格或纯度 | 2mM in Water |
运输条件 | 超低温冰袋运输 |
生化机理 | Minocycline is a tetracycline antibiotic with neuroprotective, antiapoptotic, anti-inflammatory and antimicrobial effects. Minocycline acts as a matrix metalloproteinase (MMP) inhibitor; attenuates disease severity in mouse models of multiple sclerosis. Minocycline also inhibit the enzymatic activity of poly(ADP-ribose) polymerase-1 (PARP-1) and angiogenesis. In addition, Minocycline is suggested to down-regulate CD40L on T cells and inhibit the replication of SIV and HIV. Orally active and brain penetrant.Antibiotic. Demonstrates anti-inflammatory, antiapoptotic, antioxidant and neuroprotective effects. Blood-brain barrier permeable. Matrix metalloproteinase (MMP) inhibitor (IC 50 = 290 μM at stromelysin (MMP-3). |
溶于水,遇光不稳定,味苦。
Minocycline hydrochloride has been used: · to prepare nanoliposomes to check its effect on macrophages · for the inhibition of neuroinflammation and neuropathic pain · to treat glioma in murine GL261 glioma cells
CAS编号 | 13614-98-7 |
---|---|
敏感性 | 对热敏感 |
比旋光度 | -170 to -180 deg(C=0.5、0.1mol/L HCl) |
熔点 | 205-210℃ |
沸点 | 813℃ |
储存温度 | -80℃储存 |
Reaxys-RN | 4836328 |
RTECS | QI7630500 |
分子量 | 493.94 |
分子式 | C23H27N3O7.HCl |
EC号 | 237-099-7 |
品牌 | Jinpan |
PubChem CID | 54685925 |